Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
Total Valuation
Voyager Therapeutics has a market cap or net worth of $189.70M. The enterprise value is $7.06M.
Market Cap$189.70M
Enterprise Value$7.06M
Share Statistics
Voyager Therapeutics has 55,468,807 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,468,807
Owned by Insiders2.28%
Owned by Institutions23.84%
Financial Efficiency
Voyager Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -24.01%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-24.01%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee465.12K
Profits Per Employee-377.92K
Employee Count172
Asset Turnover0.20
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Voyager Therapeutics is 5.0. Voyager Therapeutics’s PEG ratio is ―.
PE Ratio5.0
PS Ratio―
PB Ratio―
Price to Fair Value1.09
Price to FCF―
Price to Operating Cash Flow-1.88
PEG Ratio―
Income Statement
In the last 12 months, Voyager Therapeutics had revenue of 80.00M and earned -65.00M in profits. Earnings per share was -1.13.
Revenue80.00M
Gross Profit80.00M
Operating Income-83.29M
Pretax Income-64.34M
Net Income-65.00M
EBITDA-78.56M
Earnings Per Share (EPS)-1.13
Cash Flow
In the last 12 months, operating cash flow was -113.65M and capital expenditures -2.18M, giving a free cash flow of -115.83M billion.
Operating Cash Flow-113.65M
Free Cash Flow-115.83M
Free Cash Flow per Share-2.09
Dividends & Yields
Voyager Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.50
52-Week Price Change-47.63%
50-Day Moving Average3.27
200-Day Moving Average4.23
Relative Strength Index (RSI)51.23
Average Volume (3m)763.08K
Important Dates
Voyager Therapeutics upcoming earnings date is Nov 18, 2025, TBA (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date―
Financial Position
Voyager Therapeutics as a current ratio of 5.56, with Debt / Equity ratio of 16.48%
Current Ratio5.56
Quick Ratio5.56
Debt to Market Cap0.00
Net Debt to EBITDA0.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Voyager Therapeutics has paid 665.00K in taxes.
Income Tax665.00K
Effective Tax Rate-0.01
Enterprise Valuation
Voyager Therapeutics EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -15.90.
EV to Sales3.74
EV to EBITDA-3.81
EV to Free Cash Flow-15.90
EV to Operating Cash Flow-19.55
Balance Sheet
Voyager Therapeutics has $215.59M in cash and marketable securities with $40.20M in debt, giving a net cash position of -$175.39M billion.
Cash & Marketable Securities$215.59M
Total Debt$40.20M
Net Cash-$175.39M
Net Cash Per Share-$3.16
Tangible Book Value Per Share$5.20
Margins
Gross margin is 100.00%, with operating margin of -104.11%, and net profit margin of -81.25%.
Gross Margin100.00%
Operating Margin-104.11%
Pretax Margin-80.42%
Net Profit Margin-81.25%
EBITDA Margin-98.19%
EBIT Margin-104.11%
Analyst Forecast
The average price target for Voyager Therapeutics is $16.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.38
Price Target Upside378.95% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-70.38%
EPS Growth Forecast-683.06%